GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
Astepro (STO:MEDAA) has received registration approval in Europe via the decentralized procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis. National registration processes, including price and reimbursement, will now follow in each country. Launch is expected next year.
Astepro (STO:MEDAA) has received registration approval in Europe via the decentralized procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis. National registration processes, including price and reimbursement, will now follow in each country. Launch is expected next year.
